BLASUBCUTANEOUSINJECTABLE4 Generics Approved
Approved
Jun 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
NOVOLOG FLEXPEN (water injection) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2000.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOVOLOG FLEXPEN is a rapid-acting insulin analog (insulin aspart) administered via subcutaneous injection in a pre-filled pen device. Approved in 2000, it is indicated for the treatment of diabetes mellitus to improve glycemic control. The product works by mimicking the body's natural insulin response to meals, making it a cornerstone therapy in both type 1 and type 2 diabetes management. It represents a key component of intensive insulin regimens and is widely used in both basal-bolus and continuous subcutaneous insulin infusion therapies.
$1.9BPart D
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Investigation of the Analgesic Effects of Intradermal and Subdermal Sterile Water Injection on Active Labor Pain
Started Jan 2024
Why This Matters for Your Career
$1.9B Medicare spend — this is a commercially significant brand
Worked on NOVOLOG FLEXPEN at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.